UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 11, 2010
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
February 10, 2010, Oramed Pharmaceuticals Inc. issued a press release announcing
that its Chief Scientific Officer,
Miriam Kidron, Ph.D, was chosen to lecture at the Third International Conference
on Advanced Technologies and Treatments for Diabetes (ATTD) to take place in
Basel, Switzerland on February 11, 2010. Dr. Kidron will present the
following abstract in Hall B at 3:15 pm: “Assessment of Oral Insulin
Formulations in the Healthy Male Volunteers – Safety and Pharmacodynamic
Comparisons”.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated February 10,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
||||
|
Dated:
February 11, 2010
|
||||
|
By:
|
/s/
Nadav Kidron
|
|||
|
Nadav
Kidron
|
||||
|
President,
CEO and Director
|
||||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated February 10,
2010.
|
Oramed’s
Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to
Lecture
at the Third International Conference on Advanced
Technologies
and Treatments for Diabetes in Basel, Switzerland
JERUSALEM,
Israel – February 10, 2010– Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)
(www.oramed.com), a developer of alternative drug delivery systems, announced
today that its Chief Scientific Officer, Miriam Kidron, Ph.D., was chosen to
lecture at the Third International Conference on Advanced Technologies and
Treatments for Diabetes (ATTD) to take place in Basel, Switzerland on February
11, 2010. Dr. Kidron will present the following abstract in Hall B at
3:15 pm: “Assessment of Oral Insulin Formulations in the Healthy Male Volunteers
– Safety and Pharmacodynamic Comparisons”.
Based on
the conference website, the conference “presents professionals with cutting-edge
technologies from entrepreneurs racing to develop effective and advanced devices
and systems for the treatment and prevention of diabetes and related
illnesses.” For more information please visit the conference website at:
http://www2.kenes.com/attd/pages/home.aspx.
Oramed is
currently conducting a Phase 2B clinical trial in South Africa on its flagship
product an oral insulin capsule. Results are expected at the end of the first
quarter of 2010.
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center.
Oramed’s corporate and R&D headquarters are based in Jerusalem.
For more
information, please visit www.oramed.com.
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Oramed, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and Oramed’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to Oramed’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of Oramed to differ
materially from those expressed or implied in such forward looking statements.
Oramed undertakes no obligation to update or revise any forward-looking
statements.
Company
and Investor Relations Contact:
Oramed
Pharmaceuticals Inc.
Tara
Horn
USA:
+1-646-240-4193
Int’l: +
972-54-334-318
Office: +
972-2-566-0001
Email: tara@oramed.com